Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03746366 · ClinicalTrials.gov registry record · Early Phase 1
[C-11]PiB PET Imaging in Alcohol Use Disorders
A Early Phase 1 study of Alcohol Use Disorder, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT03746366: Completed Early Phase 1 study of Alcohol Use Disorder, sponsored by University of Pittsburgh.
NCT03746366 is a Early Phase 1 study of Alcohol Use Disorder that has completed, run by University of Pittsburgh. The registered enrollment target is 39 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03746366, a Early Phase 1 study of Alcohol Use Disorder, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine whether alcoholics (AUD) have a greater rate of amyloid positivity (ABeta+) compared to an age-matched cognitively normal control group (HC).
Primary Outcome
positive/negative
Conditions Studied
Interventions
- RADIATION [C-11]
- DRUG Pittsburgh Compound B
Study Locations (1)
Pennsylvania
- University of Pittsbyurgh PET Facility - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2018-12-01 |
| Est. Completion | 2020-07-01 |
| Phase | Early Phase 1 |
What the finished NCT03746366 record still lists
NCT03746366 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which [C-11] is the first listed.
NCT03746366 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03746366 about?
NCT03746366 is a clinical study titled "[C-11]PiB PET Imaging in Alcohol Use Disorders". To determine whether alcoholics (AUD) have a greater rate of amyloid positivity (ABeta+) compared to an age-matched cognitively normal control group (HC).
What is the current status of trial NCT03746366?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 39 participants. The study started on 2018-12-01. Estimated completion is 2020-07-01.
What conditions does trial NCT03746366 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT03746366?
The interventions under investigation include: [C-11] (RADIATION), Pittsburgh Compound B (DRUG).
Who is sponsoring clinical trial NCT03746366?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03746366 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03746366's enrollment target sits among peer trials
39 146th of 184 higher than 39 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impulsivity Domains and Subjective Response
RECRUITING · Early Phase 1
-
Investigating the Mu:Kappa Opioid Receptor Imbalance in Alcohol Use Disorder
RECRUITING · Early Phase 1
-
Suvorexant and Alcohol
RECRUITING · Early Phase 1
-
Anxiety During Abstinence in AUD
RECRUITING · Early Phase 1
-
Diclofenac as a KMO Inhibitor
ACTIVE NOT RECRUITING · Early Phase 1
-
Behavioral Alcohol Responses (BAR) Study
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI